MANIPULATION OF IMMUNE PROCESSES WITH HETEROCROSSLINKED ANTIBODIES

1.靶向T细胞杀伤作用存在于低密度 PBL组分。活动可以在高密度下产生 用抗CD3抗体和IL-2处理组分。 2.长期检测到有靶向的肿瘤活性 体外肿瘤生长实验。本练习驻留在T4+和 T细胞的T8+亚群。 3.抗T3和抗FCR靶向的人T细胞和K细胞， 异种交叉连接的抗肿瘤抗体已被根除 裸鼠体内的人卵巢癌细胞。 4.含有抗a抗体的异交联体抗体 与细胞表面抗体相连的可溶性抗原 抗原提呈细胞(APC)上的决定簇，大大增强 抗原呈递的效率。增强的演示文稿具有 当抗原被靶向Fc受体表面时被看到 APC上有免疫球蛋白、MHC I类和MHC II类分子。 靶向抗原呈递是抗原特异性的，而且是I-A 有限制。

1. Targeted T cell cytotoxicity resides in the low density fraction of PBL. Activity can be generated in the high density fraction by treatment with antiCD3 antibody and IL-2. 2. Targeted tumoristatic activity has been detected in a long term in vitro tumor growth assay. This activity resides in the T4+ and T8+ subsets of T cells. 3. Human T cells and K cells targeted with anti-T3 and anti-FcR, heterocrosslinked to anti-tumor antibodies eradicate established human ovarian cancer cells in nude mice. 4. Heterocrosslinked antibodies containing an antibody against a soluble antigen linked to an antibody against a cell surface determinant on an antigen presenting cell (APC), greatly enhance the efficiency of antigen presentation. Enhanced presentation has been seen when antigen was targeted to Fc receptors, surface immunoglobulin, MHC class I and MHC class II molecules on the APC. Targeted antigen presentation is antigen specific and I-A restricted.